EP0575955A1 — Process for producing staurosporine derivatives
Assigned to KH Neochem Co Ltd · Expires 1993-12-29 · 32y expired
What this patent protects
Disclosed is a process for producing a staurosporine derivative represented by Formula (I): wherein: Q represents hydrogen or -X-(CH₂) m -Y-(CH₂) n -Z or a pharmaceutically acceptable salt thereof, which comprises oxidizing a compound represented by F…
USPTO Abstract
Disclosed is a process for producing a staurosporine derivative represented by Formula (I): wherein: Q represents hydrogen or -X-(CH₂) m -Y-(CH₂) n -Z or a pharmaceutically acceptable salt thereof, which comprises oxidizing a compound represented by Formula (II) wherein Q has the same meaning as previously defined,with dimethylsulfoxide (DMSO) and an aqueous alkaline solution. Also, disclosed is a novel staurosporine derivative represented by the formula (I) wherein Q is -X-(CH₂) m -Y-(CH₂)₄-Z The staurosporine derivative (I) possesses selective protein kinase C-inhibitory and cell growth-inhibiting activities, and platelet-increasing activity.
Drugs covered by this patent
- Rydapt (MIDOSTAURIN) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.